PerkinElmer to Acquire NEN Life Sciences

Download IconDownload Print IconPrint

PerkinElmer to Acquire NEN Life Sciences

Attorney News

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

On June 12, 2000, PerkinElmer, Inc. (NYSE: PKI) announced that it had signed a definitive agreement to acquire NEN Life Sciences, Inc., a provider of state-of-the-art drug discovery products, services and technologies to the life science industry. PerkinElmer is purchasing NEN Life Sciences from an investor group led by Genstar Capital LLC for approximately $400 million. The acquisition is anticipated to close early in the third quarter and is subject to customary closing conditions and regulatory approvals.

PerkinElmer, Inc. is a $1.7 billion high technology company based in Boston, Massachusetts, operating in four businesses - life sciences, fluid sciences, optoelectronics and analytical instruments. The company has operations in over 100 countries, and is a component of the S&P 500 index.

PerkinElmer was advised in the NEN Life Sciences acquisition by the following Hale and Dorr attorneys:

  • Partners David Redlick and Hal Leibowitz, Junior Partner Rick Costello and Associates Christian Ehrbar and Dennis Sardella on corporate matters
  • Partner Jorge Contreras on intellectual property matters
  • Partner Rob Burke on tax matters
  • Partner Bill Schmidt on employee benefits matters

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel